Global event on enhancing the sustainability of investment for vaccine manufacturing in Africa.
27-29 June 2023
United Nations Conference Centre, UNECA, Addis Ababa, Ethiopia

Presentation of opportunities for investment and partnerships on vaccines and biopharmaceuticals.

A. Who we are, & what we do

<table>
<thead>
<tr>
<th>Please provide information on the company, its current portfolio, focus, specialization, and capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Armauer Hansen Research Institute (AHRI) is a clinical and biomedical research institute established in 1970 by the Government of Ethiopia through collaboration with the Save the Children Organizations of Norway and Sweden. As of 2023, AHRI has undergone through a remarkable transformation under the purview of regulation 530/2023. This regulatory update has expanded the Institute’s mandate to encompass a wide range of responsibilities, including research, development and production of vaccines, diagnostics, therapeutics, traditional medicine, nutraceutical and other pharmaceuticals. Furthermore, the Institute actively support local pharmaceutical industries to enhance and promote local production of vaccines, therapeutics and medical devices. The Institute further continues to be responsive to the challenges of emerging and reemerging diseases through medical research and innovation. In line with Ethiopia’s vision to produce vaccines, diagnostics, and pharmaceutical locally to address its internal demand and the region, AHRI with the MoH has completed comprehensive feasibility studies encompassing market, financial and technical aspects for local vaccine manufacturing. An expression of interest for consultancy and joint venture has been floated to establishment cGMP compliant vaccine, diagnostics and pharmaceuticals manufacturing capacity in Ethiopia. Our regulatory agency, Ethiopian Food and Drug Authority (EFDA), will get its maturity level shortly, and its capacity for approval and monitoring regulatory functions will be built. Similarly, our clinical trial and bioequivalence center will have full capacity to test locally produced vaccines, and pharmaceuticals to facilitate registration.</td>
</tr>
</tbody>
</table>

B. What are we offering

<table>
<thead>
<tr>
<th>Please provide information on what your company can provide to other partners, such as opportunities for partnership, technology license, training, feasibility study etc.?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Our Institutes has an open opportunity to have partnerships through joint venture to produce vaccines, pharmaceuticals, diagnostics and medical devices. Furthermore, the Institute would like to collaborate to study feasibility studies, research and development, especially to conduct clinical trials and bioequivalence studies.</td>
</tr>
</tbody>
</table>
C. What are we looking for

Please provide information on what the company seeks from other partners (businesses, finance, and technology providers)?

To promote and strengthen the local production of vaccines, diagnostics, and pharmaceuticals, we are looking for partnership for technology transfer to build research and development capacity in Ethiopia, support in exploring financing options for R&D, practical training to bring global experts to work in local manufacturing. Support toward the use of harmonization and convergence initiatives to strengthen vaccine regulatory review, and support market access for local manufacturers.

Contact:
Armauer Hansen Research Institute (AHRI),
Kolfe-Keranyo, Jimma Road, ALERT campus
Addis Ababa, Ethiopia
Email: admin@ahri.gov.et, alemseged.abdiissa@ahri.gov.et, dere_nig@hotmail.com
Tel: +251113483752
P.O. Box 1005
Website: https://ahri.gov.et/